For example, TNF blockers are newer systemic treatments for IBD, but approximately 30% of patients with Crohn’s disease do not respond to these medications and among those who do initially respond, half eventually develop tolerance [2,3]. The gene discussed is TNF; the disease is inflammatory bowel disease.